{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:55:45Z","timestamp":1790632545757,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Banca di Credito Cooperativo di Milano","award":["2022"],"award-info":[{"award-number":["2022"]}]},{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>The aim of creating an orally active non-statin cholesterol-lowering drug was achieved with bempedoic acid, a small linear molecule providing both a significant low-density lipoprotein cholesterol (LDL-C) reduction and an anti-inflammatory effect by decreasing high-sensitivity C-reactive protein. Bempedoic acid antagonizes ATP citrate-lyase, a cytosolic enzyme upstream of HMGCoA reductase which is the rate-limiting step of cholesterol biosynthesis. Bempedoic acid is a pro-drug converted to its active metabolite by very-long-chain acyl-CoA synthetase 1 which is present mostly in the liver and absent in skeletal muscles. This limits the risk of myalgia and myopathy. The remit of this review is to give clinical insights on the safety and efficacy of bempedoic acid and to understand for whom it should be prescribed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Bempedoic acid with a single daily dose (180\u00a0mg) reduces LDL-C by a mean 24.5% when given alone, by 18% when given on top of a major statin and by 38\u201340% when given in a fixed-dose combination with ezetimibe. Bempedoic acid does not lead to the risk of new-onset diabetes, and moderately improves the glycaemic profile.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>The extensive knowledge on bempedoic acid mechanism, metabolism and side effects has led to an improved understanding of the potential benefits of this agent and offers a possible alternative to cardiologists and clinical practitioners somewhat worn out today by the occurrence of the muscular side effects of statins.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11883-022-01054-2","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T12:56:34Z","timestamp":1659012994000},"page":"791-801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Bempedoic Acid: for Whom and When"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0195-7061","authenticated-orcid":false,"given":"Massimiliano","family":"Ruscica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare R.","family":"Sirtori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Carugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"issue":"15","key":"1054_CR1","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u2013504.","journal-title":"N Engl J Med"},{"issue":"9753","key":"1054_CR2","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"25","key":"1054_CR3","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"issue":"1","key":"1054_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"18","key":"1054_CR5","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","volume":"79","author":"AJ Nelson","year":"2022","unstructured":"Nelson AJ, Haynes K, Shambhu S, et al. High-intensity statin use among patients with atherosclerosis in the U.S. J Am Coll Cardiol. 2022;79(18):1802\u201313.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1054_CR6","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u201389.","journal-title":"Eur J Prev Cardiol"},{"key":"1054_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2021.08.035","volume":"334","author":"M Vrablik","year":"2021","unstructured":"Vrablik M, Seifert B, Parkhomenko A, et al. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis. 2021;334:66\u201375.","journal-title":"Atherosclerosis"},{"issue":"5","key":"1054_CR8","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.cjca.2012.05.007","volume":"28","author":"M Lemstra","year":"2012","unstructured":"Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28(5):574\u201380.","journal-title":"Can J Cardiol"},{"issue":"11","key":"1054_CR9","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","volume":"37","author":"SF Nielsen","year":"2016","unstructured":"Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016;37(11):908\u201316.","journal-title":"Eur Heart J"},{"issue":"2","key":"1054_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/jech.2009.091033","volume":"64","author":"A Shroufi","year":"2010","unstructured":"Shroufi A, Powles JW. Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. J Epidemiol Community Health. 2010;64(2):109\u201313.","journal-title":"J Epidemiol Community Health"},{"key":"1054_CR11","doi-asserted-by":"publisher","unstructured":"Bytyci I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;ehac015. https:\/\/doi.org\/10.1093\/eurheartj\/ehac015","DOI":"10.1093\/eurheartj\/ehac015"},{"key":"1054_CR12","doi-asserted-by":"publisher","unstructured":"Ruscica M, Ferri N, Banach M, Sirtori CR, Corsini A. Side effects of statins-from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovasc Res. 2022;cvac020. https:\/\/doi.org\/10.1093\/cvr\/cvac020","DOI":"10.1093\/cvr\/cvac020"},{"issue":"8","key":"1054_CR13","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43(8):830\u20133.","journal-title":"Eur Heart J"},{"issue":"10","key":"1054_CR14","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","volume":"5","author":"M Banach","year":"2020","unstructured":"Banach M, Duell PB, Gotto AM Jr, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol. 2020;5(10):1124\u201335.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"1054_CR15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1365-2362.1993.tb01286.x","volume":"23","author":"CR Sirtori","year":"1993","unstructured":"Sirtori CR, Galli C, Franceschini G. Fraudulent (and non fraudulent) fatty acids for human health. Eur J Clin Invest. 1993;23(11):686\u20139.","journal-title":"Eur J Clin Invest"},{"issue":"15","key":"1054_CR16","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1177\/2047487319845314","volume":"27","author":"CR Sirtori","year":"2020","unstructured":"Sirtori CR, Yamashita S, Greco MF, Corsini A, Watts GF, Ruscica M. Recent advances in synthetic pharmacotherapies for dyslipidaemias. Eur J Prev Cardiol. 2020;27(15):1576\u201396.","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"1054_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1021\/acs.oprd.0c00501","volume":"25","author":"DC Oniciu","year":"2021","unstructured":"Oniciu DC, Myers JL. Bempedoic acid and the fraudulent fatty acid family: the gold rush to cardiovascular therapies in the new millennium. Org Process Res Dev. 2021;25(3):8.","journal-title":"Org Process Res Dev"},{"key":"1054_CR18","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457. This is the first study demonstrating the liver-specific activation of bempedoic acid.","DOI":"10.1038\/ncomms13457"},{"issue":"7","key":"1054_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/14656566.2019.1583209","volume":"20","author":"M Ruscica","year":"2019","unstructured":"Ruscica M, Banach M, Sahebkar A, Corsini A, Sirtori CR. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opin Pharmacother. 2019;20(7):791\u2013803.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1054_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1194\/jlr.M030528","volume":"54","author":"SL Pinkosky","year":"2013","unstructured":"Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54(1):134\u201351.","journal-title":"J Lipid Res"},{"issue":"6","key":"1054_CR21","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","volume":"34","author":"MR Morrow","year":"2022","unstructured":"\u2022\u2022 Morrow MR, Batchuluun B, Wu J, et al. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia. Cell Metab. 2022;34(6):919-936 e918. This is the first study demonstrating that bempedoic acid suppresses fatty acid and cholesterol synthesis and increases fatty acid oxidation, while reducing glucose intolerance, liver steatosis, and ballooning, without increasing circulating triglycerides.","journal-title":"Cell Metab"},{"issue":"3","key":"1054_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/cts.13202","volume":"15","author":"BM Amore","year":"2022","unstructured":"Amore BM, Sasiela WJ, Ries DK, Tresh P, Emery MG. Pharmacokinetics of bempedoic acid in patients with renal impairment. Clin Transl Sci. 2022;15(3):789\u201398.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"1054_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","volume":"35","author":"CM Ballantyne","year":"2021","unstructured":"Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of bempedoic acid in clinical practice. Cardiovasc Drugs Ther. 2021;35(4):853\u201364.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1054_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.789931","volume":"8","author":"C Bardolia","year":"2021","unstructured":"Bardolia C, Amin NS, Turgeon J. Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol. Front Cardiovasc Med. 2021;8: 789931.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"1054_CR25","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1248\/bpb.33.498","volume":"33","author":"M Sato","year":"2010","unstructured":"Sato M, Mamada H, Anzai N, Shirasaka Y, Nakanishi T, Tamai I. Renal secretion of uric acid by organic anion transporter 2 (OAT2\/SLC22A7) in human. Biol Pharm Bull. 2010;33(3):498\u2013503.","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"1054_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","volume":"14","author":"HE Bays","year":"2020","unstructured":"Bays HE, Banach M, Catapano AL, et al. Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials. J Clin Lipidol. 2020;14(5):649-659 e646.","journal-title":"J Clin Lipidol"},{"issue":"Suppl E","key":"1054_CR27","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.1093\/eurheartj\/suab090","volume":"23","author":"M Ruscica","year":"2021","unstructured":"Ruscica M, Sirtori CR, Ferri N, Corsini A. New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran. Eur Heart J Suppl. 2021;23(Suppl E):E59\u201362.","journal-title":"Eur Heart J Suppl"},{"key":"1054_CR28","doi-asserted-by":"publisher","unstructured":"Jadhav SB, Crass RL, Chapel S, et al. Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. Eur Heart J Cardiovasc Pharmacother. 2021;pvab064. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab064","DOI":"10.1093\/ehjcvp\/pvab064"},{"issue":"2","key":"1054_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MED.0000000000000706","volume":"29","author":"A Pirillo","year":"2022","unstructured":"Pirillo A, Catapano AL. New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes. 2022;29(2):161\u20136.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1054_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","volume":"277","author":"CM Ballantyne","year":"2018","unstructured":"Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195\u2013203.","journal-title":"Atherosclerosis"},{"issue":"3","key":"1054_CR31","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jacl.2022.03.001","volume":"16","author":"U Laufs","year":"2022","unstructured":"Laufs U, Ballantyne CM, Banach M, Bays H, Catapano AL, Duell PB, Goldberg AC, Gotto AM, Leiter LA, Ray KK, Bloedon LT, MacDougall D, Zhang Y, Mancini GBJ. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol. 2022;16(3):286\u201397.","journal-title":"J Clin Lipidol."},{"key":"1054_CR32","unstructured":"Nilemdo [https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nilemdo]. Accessed 19 July 2022."},{"key":"1054_CR33","unstructured":"Nustendi [https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nustendi#product-information-section].\u00a0Accessed 19 July 2022."},{"issue":"11","key":"1054_CR34","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"18","key":"1054_CR35","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780\u20138.","journal-title":"JAMA"},{"issue":"7","key":"1054_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7): e011662.","journal-title":"J Am Heart Assoc"},{"key":"1054_CR37","doi-asserted-by":"crossref","unstructured":"Ballantyne CM, Banach M, Bays HE, et al. Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and\/or heterozygous familial hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). Am J Cardiol. 2022;174:1\u201311.","DOI":"10.1016\/j.amjcard.2022.03.020"},{"key":"1054_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104916","volume":"159","author":"M Ruscica","year":"2020","unstructured":"Ruscica M, Corsini A, Ferri N, Banach M, Sirtori CR. Clinical approach to the inflammatory etiology of cardiovascular diseases. Pharmacol Res. 2020;159: 104916.","journal-title":"Pharmacol Res"},{"issue":"12","key":"1054_CR39","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"1054_CR40","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.amjcard.2010.03.018","volume":"106","author":"PM Ridker","year":"2010","unstructured":"Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol. 2010;106(2):204\u20139.","journal-title":"Am J Cardiol"},{"issue":"7","key":"1054_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003121","volume":"17","author":"AFG Cicero","year":"2020","unstructured":"Cicero AFG, Fogacci F, Hernandez AV, et al. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis. PLoS Med. 2020;17(7): e1003121.","journal-title":"PLoS Med"},{"issue":"1","key":"1054_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40261-020-00989-1","volume":"41","author":"AS Bhagavathula","year":"2021","unstructured":"Bhagavathula AS, Al Matrooshi NO, Clark CCT, Rahmani J. Bempedoic acid and ezetimibe for the treatment of hypercholesterolemia: a systematic review and meta-analysis of randomized phase II\/III trials. Clin Drug Investig. 2021;41(1):19\u201328.","journal-title":"Clin Drug Investig"},{"issue":"15","key":"1054_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.016262","volume":"9","author":"A Di Minno","year":"2020","unstructured":"Di Minno A, Lupoli R, Calcaterra I, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020;9(15): e016262.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"1054_CR44","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380\u201390.","journal-title":"Nat Rev Rheumatol"},{"key":"1054_CR45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","volume":"320","author":"J Rubino","year":"2021","unstructured":"Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial. Atherosclerosis. 2021;320:122\u20138.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1054_CR46","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jacl.2021.05.002","volume":"15","author":"J Rubino","year":"2021","unstructured":"Rubino J, MacDougall DE, Sterling LR, Kelly SE, McKenney JM, Lalwani ND. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: a randomized, controlled trial. J Clin Lipidol. 2021;15(4):593\u2013601.","journal-title":"J Clin Lipidol"},{"issue":"18","key":"1054_CR47","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.jacc.2022.02.046","volume":"79","author":"MD Kelsey","year":"2022","unstructured":"Kelsey MD, Nelson AJ, Green JB, et al. Guidelines for cardiovascular risk reduction in patients with type 2 diabetes: JACC Guideline comparison. J Am Coll Cardiol. 2022;79(18):1849\u201357.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1054_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12933-020-01101-9","volume":"19","author":"X Wang","year":"2020","unstructured":"Wang X, Zhang Y, Tan H, et al. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020;19(1):128.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1054_CR49","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/dom.14645","volume":"24","author":"LA Leiter","year":"2022","unstructured":"Leiter LA, Banach M, Catapano AL, et al. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes Obes Metab. 2022;24(5):868\u201380.","journal-title":"Diabetes Obes Metab"},{"key":"1054_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.879355","volume":"9","author":"X Xiao","year":"2022","unstructured":"Xiao X, Luo Y, Peng D. Updated understanding of the crosstalk between glucose\/insulin and cholesterol metabolism. Front Cardiovasc Med. 2022;9: 879355.","journal-title":"Front Cardiovasc Med"},{"issue":"34","key":"1054_CR51","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"key":"1054_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2021.11.021","volume":"340","author":"AL Catapano","year":"2022","unstructured":"Catapano AL, Ray KK, Tokgozoglu L. Prevention guidelines and EAS\/ESC guidelines for the treatment of dyslipidaemias: a look to the future. Atherosclerosis. 2022;340:51\u20132.","journal-title":"Atherosclerosis"},{"issue":"40","key":"1054_CR53","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1093\/eurheartj\/ehaa034","volume":"41","author":"A Allahyari","year":"2020","unstructured":"Allahyari A, Jernberg T, Hagstrom E, Leosdottir M, Lundman P, Ueda P. Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. Eur Heart J. 2020;41(40):3900\u20139.","journal-title":"Eur Heart J"},{"issue":"9","key":"1054_CR54","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.clinthera.2021.07.019","volume":"43","author":"C Blaum","year":"2021","unstructured":"Blaum C, Brunner FJ, Gossling A, et al. Target populations and treatment cost for bempedoic acid and PCSK9 inhibitors: a simulation study in a contemporary CAD cohort. Clin Ther. 2021;43(9):1583\u2013600.","journal-title":"Clin Ther"},{"issue":"15","key":"1054_CR55","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.jacc.2021.08.011","volume":"78","author":"K Oyama","year":"2021","unstructured":"Oyama K, Giugliano RP, Blazing MA, et al. Baseline low-density lipoprotein cholesterol and clinical outcomes of combining ezetimibe with statin therapy in IMPROVE-IT. J Am Coll Cardiol. 2021;78(15):1499\u2013507.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1054_CR56","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.5114\/aoms\/141941","volume":"17","author":"M Banach","year":"2021","unstructured":"\u2022\u2022 Banach M, Burchardt P, Chlebus K, et al. PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021;17(6):1447\u2013547. These are the first guidelines on diagnosis and therapy of lipid disorders describing recommendations on the use of bempedoic acid.","journal-title":"Arch Med Sci"},{"issue":"1","key":"1054_CR57","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jacl.2021.11.013","volume":"16","author":"BA Warden","year":"2022","unstructured":"Warden BA, Cardiology BA, Purnell JQ, Duell PB, Fazio S. Real-world utilization of bempedoic acid in an academic preventive cardiology practice. J Clin Lipidol. 2022;16(1):94\u2013103.","journal-title":"J Clin Lipidol"},{"issue":"3 Suppl","key":"1054_CR58","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","volume":"8","author":"JR Guyton","year":"2014","unstructured":"Guyton JR, Bays HE, Grundy SM, Jacobson TA. The National Lipid Association Statin Intolerance P: an assessment by the statin intolerance panel: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S72-81.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"1054_CR59","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jacl.2021.07.002","volume":"15","author":"AM Agha","year":"2021","unstructured":"Agha AM, Jones PH, Ballantyne CM, Virani SS, Nambi V. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). J Clin Lipidol. 2021;15(5):649\u201352.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"1054_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003911","volume":"19","author":"A Kaura","year":"2022","unstructured":"Kaura A, Hartley A, Panoulas V, et al. Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: a cohort study. PLoS Med. 2022;19(2): e1003911.","journal-title":"PLoS Med"},{"key":"1054_CR61","doi-asserted-by":"crossref","unstructured":"Stroes ESG: Factors that influence bempedoic acid-mediated reductions in high-sensitivity C-reactive protein: analysis of pooled patient-level data from phase 3 clinical trials. In: ACC20 Together With World Congress of Cardiology. vol. 75. Chicago; 2020: 1916.","DOI":"10.1016\/S0735-1097(20)32543-2"},{"key":"1054_CR62","doi-asserted-by":"crossref","unstructured":"Penson PE, Bruckert E, Marais D, Reiner \u017d, Pirro M, Sahebkar A, Bajraktari G, Mirrakhimov E, Rizzo M, Mikhailidis DP, Sachinidis A et al. Step\u2010by\u2010step diagnosis and management of the nocebo\/drucebo effect in statin\u2010associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).\u00a0J Cachexia Sarcopenia Muscle. 2022;13:1596\u20131622.","DOI":"10.1002\/jcsm.12960"},{"key":"1054_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2020.100144","volume":"5","author":"BA Warden","year":"2021","unstructured":"Warden BA, Purnell JQ, Duell PB, et al. Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice. Am J Prev Cardiol. 2021;5: 100144.","journal-title":"Am J Prev Cardiol"},{"issue":"25","key":"1054_CR64","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.119.041974","volume":"140","author":"R Khera","year":"2019","unstructured":"Khera R, Valero-Elizondo J, Das SR, et al. Cost-related medication nonadherence in adults with atherosclerotic cardiovascular disease in the United States, 2013 to 2017. Circulation. 2019;140(25):2067\u201375.","journal-title":"Circulation"},{"key":"1054_CR65","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","volume":"235","author":"S Nicholls","year":"2021","unstructured":"Nicholls S, Lincoff AM, Bays HE, et al. Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021;235:104\u201312.","journal-title":"Am Heart J"},{"issue":"12","key":"1054_CR66","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1136\/heartjnl-2013-303640","volume":"99","author":"JA Dorresteijn","year":"2013","unstructured":"Dorresteijn JA, Visseren FL, Wassink AM, et al. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 2013;99(12):866\u201372.","journal-title":"Heart"},{"key":"1054_CR67","doi-asserted-by":"crossref","unstructured":"Gunn LH, McKay AJ, Feng A, Louie MJ, Ballantyne CM, Ray KK. Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. Atherosclerosis Plus. 2022;49:20e27.","DOI":"10.1016\/j.athplu.2022.05.003"},{"issue":"11","key":"1054_CR68","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","volume":"380","author":"BA Ference","year":"2019","unstructured":"Ference BA, Ray KK, Catapano AL, et al. Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med. 2019;380(11):1033\u201342.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01054-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-022-01054-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01054-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T10:27:05Z","timestamp":1663151225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-022-01054-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1007\/s11883-022-01054-2","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"5 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.C. has received honoraria from Amgen, AstraZeneca, Daiichi Sankyo, Novartis, Recordati, Servier, and Sanofi and a grant from Daiichi Sankyo. M.R. received a grant from Daiichi Sankyo; M.B. speakers bureau: Amgen, Esperion, Herbapol, Kogen, KRKA, Novartis, Polpharma, Sanofi, Servier, Teva, Viatris, and Zentiva; consultant to Akcea, Amgen, Daichii Sankyo, Esperion, Freia Pharmaceuticals, Polfarmex, and Sanofi; and grants from Amgen, Viatris, Sanofi, and Valeant. S.C. has received payment or honoraria from Fidia, Techdow, and Bruno. C.R.S. has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}